Biogen Inc. (BIIB)

234,64 +0,56 (+0,24%) Börsenschluss: 04:00PM EST

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
https://www.biogen.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 8.725

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Christopher A. Viehbacher	President, CEO & Director	487,94k	N/A	1961
Mr. Michael R. McDonnell CPA	Executive VP & CFO	2,12M	N/A	1964
Ms. Nicole Murphy	Head of Pharmaceutical Operations & Technology	1,46M	N/A	N/A
Ms. Susan H. Alexander Esq.	Executive VP & Chief Legal Officer	2,2M	N/A	1957
Dr. Ginger Gregory	Executive VP & Chief Human Resources Officer	1,59M	N/A	1968
Ms. Robin C. Kramer	Senior VP & Chief Accounting Officer	N/A	N/A	1966
Mr. Charles E. Triano	Senior VP & Head of Investor Relations	N/A	N/A	N/A
Ms. Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	N/A	N/A	N/A
Mr. Adam Keeney Ph.D.	Executive VP & Head of Corporate Development	N/A	N/A	N/A
Ms. Alisha A. Alaimo	President & Head of North America	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Biogen Inc.s ISS Governance QualityScore, Stand 1. Dezember 2023, lautet 6. Die grundlegenden Scores sind Audit: 9, Vorstand: 4, Shareholderrechte: 2, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.